FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
Fri December 14, 2018 4:00 PM|PR Newswire|About: AMGN
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD
Fri December 14, 2018 12:00 PM|Business Wire|About: TKPYY
Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications
Fri December 14, 2018 6:31 PM|Business Wire|About: TEVA
Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab)
Fri December 14, 2018 10:29 AM|Business Wire|About: PFE
Tue September 17, 2019 4:11 PM|PR Newswire|About: NBIX
PR Newswire
SAN DIEGO, Sept.17, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX)
Tue September 17, 2019 8:00 AM|Business Wire|About: SGEN
– First Presentation of Initial Data from a Phase 1 Trial of Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session –
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN)
FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
Thu December 6, 2018 5:11 PM|Business Wire|About: RHHBY
Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend
Fri December 7, 2018 4:00 PM|PR Newswire|About: AMGN
Tue September 17, 2019 6:45 AM|Business Wire|About: MRK
Merck (MRK) Continues to Expand Investigational Supply to Support International Ebola Outbreak Response
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck, known as MSD outside the United States and Canada
Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
Mon December 10, 2018 2:00 AM|Business Wire|About: BMY
Novartis' Kisqali extends PFS in late-stage breast cancer studies
Dec. 10, 2018 7:38 AM ET|About: Novartis AG (NVS)|By: Douglas W. House, SA News Editor
BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress
Mon December 10, 2018 6:05 AM|GlobeNewswire|About: BGNE
Wed September 18, 2019 9:25 AM|Business Wire|About: BLUE
Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of Follow-up
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE)
September 12, 2019 04:00 AM Eastern Daylight Time
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS)
Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors
Fri December 14, 2018 6:45 AM|PR Newswire|About: LLY
BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress
Sat December 15, 2018 2:30
CAMBRIDGE, Mass. and BEIJING, China, Dec. 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) AM|GlobeNewswire|About: BGNE
Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
Fri December 14, 2018 8:00 AM|Business Wire|About: PFE
Abiomed Announces Preliminary Q3 FY 2019 Revenue of $201 Million, Up 30% Over Prior Year and Increases Full Year Guidance
Mon January 7, 2019 7:00 AM|Business Wire|About: ABMD
DANVERS, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- Abiomed, Inc. (ABMD) (NASDAQ: ABMD)
Regeneron to receive $462M from Sanofi in revamped I-O collaboration
Jan. 7, 2019 7:22 AM ET|About: Regeneron Pharmaceutic... (REGN)|By: Douglas W. House, SA News Editor
Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension
Mon January 7, 2019 7:45 AM|PR Newswire|About: AGN
01.07.2019 | Investors
Allergan to Establish R&D Presence in Cambridge, Massachusetts
- The facility, located in Kendall Square, is expected to open in 1Q2019 -
DUBLIN, Jan. 7, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN),
Celgene Corporation Announces 2019 Financial Guidance and Key Milestones
Mon January 7, 2019 7:30 AM|Business Wire|About: CELG
Bausch + Lomb Announces HEALTH CANADA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution, 0.024%) for the Treatment of Glaucoma
Thu January 3, 2019 7:30 AM|Canada Newswire|About: BHC
LAVAL, QC, Jan. 3, 2019 /CNW Telbec/ - Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health (BHC) (TSX : BHC)
New Prediction Feature for Hypoglycemia Now Available in Sugar.IQ(TM) Personal Diabetes Assistant App, Developed by Medtronic and IBM Watson Health
Thu January 3, 2019 9:00 AM|InPublic US|About: MDT
New Data Published in the International Journal of Neuropsychopharmacology Support that Rapastinel May Produce Rapid and Sustained Antidepressant Effects Through a Potentially Novel Mechanism of Action
Thu January 3, 2019 7:45 AM|PR Newswire|About: AGNPR Newswire
DUBLIN, Jan. 3, 2019 /PRNewswire/ -- Allergan plc (AGN)
First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis
Thu January 3, 2019 7:30 AM|GlobeNewswire|About: BIIB
Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies
Thu January 3, 2019 8:00 AM|Business Wire|About: VRTX
Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Wed January 2, 2019 4:25 PM|Business Wire|About: BMY
BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference
January 02, 2019 | About: BCTXF +0% MRK +0%
BERKELEY, Calif., and VANCOUVER, British Columbia, Jan. 02, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (BCTXF) ("BriaCell" or the "Company")
Merck’s KEYTRUDA® (pembrolizumab) Receives Five New Approvals in Japan, Including in Advanced Non-Small Cell Lung Cancer (NSCLC), as Adjuvant Therapy for Melanoma, and in Advanced Microsatellite Instability-High (MSI-H) Tumors
Thu January 3, 2019 6:45 AM|Business Wire|About: MRK
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
THURSDAY, JANUARY 3, 2019 6:58 AM EST
NEW YORK & SUMMIT, N.J.,--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG)
Biogen Applauds Quebec Decision to Cover SPINRAZA™ (nusinersen) for a broad population of SMA Patients
Thu December 20, 2018 12:19 PM|GlobeNewswire|About: BIIB
Alexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Fri December 21, 2018 11:23 AM|Business Wire|About: ALXN
Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T™ Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndrome (MDS)
Fri December 21, 2018 12:35 PM|PR Newswire|About: XON
Fri September 27, 2019 8:00 AM|Business Wire|About: INCY
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (INCY)
Sanofi: FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine
FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine
PARIS and KENILWORTH, N.J. - December 26, 2018
Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder
Fri December 21, 2018 3:19 PM|Business Wire|About: TEVA
AbbVie Submits New Drug Application to U.S. FDA and Marketing Authorization Application to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis
Thu December 20, 2018 8:50 AM|PR Newswire|About: ABBV
Bevespi Aerosphere approved in the EU for chronic obstructive pulmonary disease
20 December 2018 13:45 GMT
December 20, 2018
Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies
FOSTER CITY, Calif. & LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 20, 2018-- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc.(NASDAQ: AGEN)
Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial
Thu December 20, 2018 4:15 PM|Business Wire|About: MRK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer
Wed December 19, 2018 4:13 PM|Business Wire|About: MRK
LYNPARZA® (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer
Wed December 19, 2018 4:01 PM|Business Wire|About: AZN
Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program
Thu December 20, 2018 7:30 AM|PR Newswire|About: XON
KEYTRUDA is a prescription medicine used to treat:
PD‑L1 = programmed death ligand 1;
EGFR = epidermal growth factor receptor;
ALK = anaplastic lymphoma kinase;
HER2/neu = human epidermal growth factor receptor 2.
LYNPARZA is a prescription medicine used to treat adults who have:
Amgen Submits Supplemental Biologics License Application For Nplate® (romiplostim)
Wed December 19, 2018 4:00 PM|PR Newswire|About: AMGN
Lilly Announces Financial Guidance, Reviews Commercial Performance, and Highlights Promising Pipeline Opportunities at Investment Community Meeting
12/19/2018
INDIANAPOLIS, Dec. 19, 2018 /PRNewswire/ -
2019 revenue is expected to be between $25.3 billion and $25.8 billion
Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies
12/18/2018
INDIANAPOLIS and BERKLEY, Calif., Dec. 18, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO)
Lilly Announces 15 Percent Dividend Increase
Wed December 19, 2018 6:25 AM|PR Newswire|About: LLY
STING is known to be a central mediator of innate immunity. When stimulated, STING induces the expression of type I interferon, cytokines and T cell recruitment factors that result in the activation of macrophages and dendritic cells, innate effector cells such as natural killer (NK) cells, and priming of tumor-specific T cells.
Aduro’s STING Pathway Activator platform is based on the activation of the cytoplasmic STING (Stimulator of Interferon Genes) receptor to lead to a tumor-specific immune response.
Natural STING Pathway Activators are small molecules expressed by bacteria and immune cells. Aduro has established pioneering expertise in STING Pathway Activator technology and, working in collaboration with academic leaders in the field, has developed synthetic STING Pathway Activators with significantly higher activity than the natural STING ligands produced by bacteria and mammalian cells. These synthetic STING Pathway Activators are being developed for direct injection into tumors to stimulate an immune response against antigens present in the tumor. The process is expected to use the tumor itself as a “vaccine,” enabling the induction of a tumor-specific immune response that is unique to the treated individual; an off-the-shelf small molecule approach to personalized immunotherapy.
NEW BRUNSWICK, N.J., Dec. 14, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today issued the following statement regarding speculation about the safety of our products.
The Reuters article is one-sided, false, and inflammatory. Johnson & Johnson's baby powder is safe and asbestos-free. Studies of more than 100,000 men and women show that talc does not cause cancer or asbestos-related disease. Thousands of independent tests by regulators and the world's leading labs prove our baby powder has never contained asbestos. Johnson & Johnson will continue to defend the safety of our product. For the truth and facts about talc, please go to www.factsabouttalc.com.
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
Mon December 17, 2018 9:00 AM|PR Newswire|About: AMGN
Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China
Sun December 16, 2018 5:40 PM|Business Wire|About: INCY
BeiGene's tislelizumab shows positive action in early-stage cancer study
Dec. 17, 2018 12:09 PM ET|About: BeiGene (BGNE)|By: Douglas W. House, SA News Editor
Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies
Mon December 17, 2018 8:00 AM|PR Newswire|About: PFE
Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis
Tue December 18, 2018 6:45 AM|PR Newswire|About: LLY
Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150
Tue December 18, 2018 8:30 AM|Business Wire|About: VRTX
FDA Approves Smart Programmer for the InterStim System
(GLOBE NEWSWIRE via COMTEX) --Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence
DUBLIN - December 17, 2018 - Medtronic plc (NYSE:MDT)
Bristol-Myers Squibb and Boston Medical Center Announce Research Collaboration to Investigate Markers of Immuno-Oncology Response and Resistance
Mon December 17, 2018 4:30 PM|Business Wire|About: BMY
NEW YORK & BOSTON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) (NYSE:BMY), and Boston Medical Center,
FibroGen's roxadustat OK'd in China for CKD patients on dialysis
Dec. 18, 2018 7:01 AM ET|By: Douglas W. House, SA News Editor
Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases
Mon December 17, 2018 7:00 AM|PR Newswire|About: AZN
Pyramid Biosciences, Inc. (www.pyramidbio.com)
Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3’s RNA Splicing Platform
Mon December 17, 2018 6:59 AM|Business Wire|About: BMY
Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Mon December 17, 2018 6:45 AM|PR Newswire|About: LLY
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Mon December 17, 2018 6:59 AM|Business Wire|About: BMY
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections
Wed December 12, 2018 10:30 AM|Business Wire|About: MRK
Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions
Tue December 11, 2018 4:00 PM|PR Newswire|About: AMGN
Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
Thu December 13, 2018 6:30 AM|PR Newswire|About: LLY
Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease
Thu December 13, 2018 8:00 AM|Business Wire|About: VRTX
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
Wed December 12, 2018 7:00 AM|PR Newswire|About: JNJ
Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials
Mon December 10, 2018 4:41 PM|PR Newswire|About: AMGN
Athenex's Oraxol shows encouraging action in early-stage gastric cancer study
Dec. 11, 2018 8:19 AM ET|By: Douglas W. House, SA News Editor
BioLineRx up 2% premarket on start of triple combo arm in mid-stage pancreatic cancer study
Dec. 11, 2018 7:40 AM ET|About: BioLineRx Ltd. (BLRX)|By: Douglas W. House, SA News Editor
Medtronic Named One of America's Best Corporate Citizens in 2018 by Forbes Magazine
Mon December 10, 2018 10:30 AM|InPublic|About: MDT
Entera Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious Illnesses
JERUSALEM, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX)
Illumina Announces a New Genotyping Array and Scientific Contribution to Three Genome Centers to Support the All of Us Research Program
Thu December 6, 2018 4:05 PM|Business Wire|About: ILMN
Novartis' alpelisib improved PFS in certain breast cancer patients in late-stage study
Dec. 6, 2018 12:07 PM ET|By: Douglas W. House, SA News Editor
Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses
Wed December 5, 2018 8:00 AM|PR Newswire|About: BHC
Bristol-Myers Squibb Announces Dividend Increase
Thu December 6, 2018 4:15 PM|Business Wire|About: BMY
Stryker increases dividend 11%, declaring a $0.52 per share quarterly dividend
Tue December 4, 2018 3:30 PM|GlobeNewswire|About: SYK
IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018
Tue December 4, 2018 11:52 AM|PR Newswire|About: ABBV
Johnson & Johnson's Darzalex shows positive effect in certain multiple myeloma patients;
Dec. 4, 2018 11:56 AM ET|By: Douglas W. House, SA News Editor
Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
Wed December 5, 2018 8:15 AM|Business Wire|About: RHHBY
FDA Grants Priority Review to Genentech’s Tecentriq in Combination with Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer
Wed December 5, 2018 1:00 AM|Business Wire|About: RHHBY
Celgene's CAR-T JCARH125 shows positive action in early-stage multiple myeloma study
Dec. 4, 2018 7:35 AM ET|About: Celgene Corporation (CELG)|By: Douglas W. House, SA News Editor
Gilead CAR-T therapy shows sustained benefit in treatment-resistant ALL patients
Dec. 4, 2018 7:17 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
Seattle Genetics' Adcetris shows treatment effect in CD30+ PTCL
Dec. 4, 2018 7:57 AM ET|About: Seattle Genetics, Inc. (SGEN)|By: Douglas W. House, SA News Editor
Clovis Oncology Announces Positive Outcome in European Opposition Proceeding Related to Rubraca®
Tue December 4, 2018 7:37 AM|Business Wire|About: CLVS
Comprehensive Positive Phase 3 Data for Alexion’s ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood
Mon December 3, 2018 2:32 PM|Business Wire|About: ALXN
December 3, 2018
IMBRUVICA® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NORTH CHICAGO, Ill., Dec. 3, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV
Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit
Mon December 3, 2018 10:00 AM|Business Wire|About: INCY
BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting
Mon December 3, 2018 2:15 PM|GlobeNewswire|About: BGNE
NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment
Mon December 3, 2018 10:15 AM|PR Newswire|About: LLY
New Venclexta® Data Demonstrate Deep Responses in Two of the Most Common Types of Leukemia
Mon December 3, 2018 1:30 PM|Business Wire|About: RHHBY
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Sat December 1, 2018 12:00 PM|PR Newswire|About: REGN
TARRYTOWN, N.Y., Dec. 1, 2018 /PRNewswire/
AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course
Sat December 1, 2018 5:47 PM|PR Newswire|About: ABBV
IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton's Tyrosine Kinase Inhibitor to Date
Sun December 2, 2018 12:00 PM|PR Newswire|About: ABBV
Pfizer's Rituxan biosimilar successful in late-stage study; shares up 1% premarket
Dec. 3, 2018 7:08 AM ET|About: Pfizer Inc. (PFE)|By: Douglas W. House, SA News Editor
Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R²) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018
Sun December 2, 2018 7:35 PM|Business Wire|About: CELG
Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting
Sat December 1, 2018 12:00 PM|Business Wire|About: SGEN
Copyright © 2018 seeking biotech alpha - All Rights Reserved. City Photos from Pixabay
Powered by GoDaddy Website Builder